Internation No PCT/GB 03/03669

a. classification of subject matter IPC 7 A61K38/08 A61K A61K38/25 A61P9/10 According to International Patent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 A61K A61P C07K Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE, CHEM ABS Data C. DOCUMENTS CONSIDERED TO BE RELEVANT Category ° Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. X WO OO 23097 A (SAHLTECH AB ; ANGELIN BO 1-5 (SE); RUDLING MATS (SE)) 11-16, 27 April 2000 (2000-04-27) 22,26 claims page 4, paragraph 3 X WO 98 22124 A (GENNARO COLONNA VITO DE 1-4, ; BOGHEN MUNY (IT); BERTI FERRUCCIO (IT); 12-15, M) 28 May 1998 (1998-05-28) 22,24-26 claims examples page 26, paragraph 1 X WO OO 67770 A (SAHLTECH AB ; BOLLANO ENTELA (SE); ISGAARD JOERGEN (SE); OMEROVIC E) 1,3,12, 14,15,26 16 November 2000 (2000-11-16) claims X Further documents are listed in the continuation of box C. Patent family members are listed in annex. Special categories of cited documents: "T" later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the *A* document defining the general state of the art which is not considered to be of particular relevance invention "E" earlier document but published on or after the International "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled "O" document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed "&" document member of the same patent family Date of the actual completion of the international search Date of mailing of the international search report 14 November 2003 28/11/2003 Name and mailing address of the ISA Authorized officer European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016 Böhmerova, E

Internati ipplication No PCT/GB 03/03669 Ä

CICconti	ANAL DOGUMENTO CONSTRUCTOR	PCT/GB 03/03669						
C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT Category • Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No.								
	of about of accument, with intuication, where appropriate, of the relevant passages	Helevant to claim No.						
X	WO 00 09537 A (UNIV TULANE ;BOWERS CYRIL Y (US); LIANG YONGWU (US); MOMANY FRANK) 24 February 2000 (2000-02-24) claims page 24, paragraph 3	1,3,5,6, 12,14, 16,17,26						
X	BROGLIO FABIO ET AL: "Effects of acute hexarelin administration on cardiac performance in patients with coronary artery disease during by-pass surgery" EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 448, no. 2-3, 19 July 2002 (2002-07-19), pages 193-200, XP002261551 ISSN: 0014-2999 abstract page 198, left-hand column, last paragraph	1,3,4, 12,14, 15,26						
X	WALKER RICHARD F ET AL: "Effects of stimulated growth hormone secretion on age-related changes in plasma cholesterol and hepatic low density lipoprotein messenger RNA concentrations" MECHANISMS OF AGEING AND DEVELOPMENT, vol. 75, no. 3, 1994, pages 215-226, XP009021106 ISSN: 0047-6374 abstract; figure 2	1,2,4,5, 11-13, 16,22, 23,26						
X	MARLEAU S ET AL: "Effect of growth hormone releasing peptides (GHRPs) on monocyte/macrophage scavenger receptors (SR) B (CD36) expression and monocyte trafficking" INFLAMMATION RESEARCH, vol. 50, no. Supplement 3, September 2001 (2001-09), page S154 XP009021107 5th World Congress on Inflammation; Edinburgh, Scotland; September 22-26, 2001 ISSN: 1023-3830 abstract	7,10,11, 18,21						
A	BODART V ET AL: "CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart" CIRCULATION RESEARCH, vol. 90, no. 8, 3 May 2002 (2002-05-03), pages 844-849, XP002261552 ISSN: 0009-7330 abstract	7,10,11, 18						

Internation No. PCT/GB 03/03669

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 1-11 and 23-25 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. X Claims Nos.: 8,19,23,24 (all partialy) because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This International Searching Authority found multiple inventions in this International application, as follows:
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
A seek some of the conductive of a seek force were the set of the state of the seek seek force were the set of the seek seek force were the seek seek seek force were the seek seek seek force were the seek seek seek seek seek seek seek se
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest The additional search fees were accompanied by the applicant's protest.
No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 8,19,23,24 (all partialy)

Present claims 8 and 19 relate to a genes defined by reference to a desirable characteristic or property, namely to genes involved in cellular cholesterol efflux.

The claims cover all genes having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such genes. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the genes LXRalpha and ABCA1 as defined in claims 9 and 20.

Present claims 23 and 24 relate to a compounds defined by reference to a desirable characteristic or property, namely to CD36 ligand. The claims cover all compounds having this characteristic or property, whereas the application does not provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for any such compound. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the GHRPs and derived peptidomimetics.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

Internai Application No PCT/GB 03/03669

	ent document in search report		Publication date		Patent family member(s)		Publication date
MO	0023097	A	27-04-2000	AU	764779	B2	28-08-2003
				ΑU	1428800	Α	08-05-2000
				CA	2342794	A1	27-04-2000
				EP	1124571	A1	22-08-2001
				JP	2002527486	T	27-08-2002
				WO		Å1	27-04-2000
				ÜS	6559289	B1	06-05-2003
WO	9822124	Α	28-05-1998	ΑU	5142498	Α	10-06-1998
	, , , , , , , , , , , , , , , , , , , ,			WO	9822124	A1	28-05-1998
WO	0067770	Α	16-11-2000	ΑU	4790800	Α	21-11-2000
				EP	1173190	A1	23-01-2002
				WO	0067770	A1	16-11-2000
WO	0009537	Α	24-02-2000	AU	5671099		06-03-2000
				EP		A2	05-12-2001
				JP	2002525265	Ţ	13-08-2002
				WO		A2	24-02-2000
				US		A1	17-10-2002
				US	6468974	B1	22-10-2002